Metropolis Healthcare announced strong Q3 FY26 results, marked by a 15% YoY increase in organic revenue and a 29% YoY rise in EBITDA. The company continues to see momentum in preventive and wellness health checks and specialty testing, contributing to overall growth. For 9MFY26, organic revenue grew by 13% YoY, with EBITDA up by 18%.
Financial Performance Highlights
Metropolis Healthcare reported a robust performance for Q3 FY26. Key highlights include:
- Revenue: INR 371 Cr, up 15% YoY (Organic)
- EBITDA: INR 93 Cr, up 29% YoY (Organic), margin expanded to 25.0%
- PAT: INR 48 Cr, up 52% YoY (Organic)
For 9MFY26, the company demonstrated consistent growth:
- Revenue: INR 1,118 Cr, up 13% YoY (Organic)
- EBITDA: INR 285 Cr, up 18% YoY (Organic)
- PAT: INR 147 Cr, up 26% YoY (Organic)
Segment Performance
Key performance indicators for Q3 FY26 include:
- Patient Volume: 3.3 Mn, up 9% YoY
- B2C Revenue: INR 223 Cr, up 15% YoY
- B2B Revenue: INR 148 Cr, up 15% YoY
- Test Volume: 7.0 Mn, up 8% YoY
Business Updates and Strategic Initiatives
The company is focused on key strategic initiatives:
- TruHealth: Revenue grew by 25% YoY for Q3 FY26, with contribution increasing to 19% of mix.
- Specialty Revenue: Grew by 16% YoY, leveraging diagnostic capabilities and strengthening leadership through science and clinician trust.
Metropolis 3.0 Strategy
Metropolis is executing its 3.0 strategy, focusing on strengthening the core business, expanding into adjacencies, bolt-on acquisitions, and fostering sustainability. The strategy aims to drive revenue growth and achieve pre-COVID margin profiles.
ESG Goals
The company is committed to Environmental, Social, and Governance (ESG) goals, including carbon neutrality by 2043 and achieving zero waste and water neutrality.
Source: BSE
